[pending] CLOTRIMAZOLE (CLOTRIMAZOLE)
Pending LLM rewrite. Source: FDA_DRUG D-0210-2026.
- Product
- CLOTRIMAZOLE — CLOTRIMAZOLE (CLOTRIMAZOLE)
- Category
- Drug
- Distribution
- Distributed nationwide
Category
FDA recalls of prescription and over-the-counter drugs.
FDA drug recalls cover prescription medicines, over-the-counter products, biologic and gene therapies, and active pharmaceutical ingredients (the raw drug substances that manufacturers compound into finished products). Recall classifications follow the same Class I / II / III system as food, and most published recalls are Class II — the product is unlikely to cause permanent harm but doesn't meet specification.
The most common reasons for a drug recall are out-of-specification potency or dissolution (the active ingredient is present in too high or too low a dose), microbial contamination, particulate matter in injectables, mix-ups during packaging where bottles end up with the wrong tablets, and nitrosamine impurities in certain drug classes. Many drug recalls are at the lot level — the manufacturer's whole product line is still safe to use, but specific production lots are pulled.
If a recall affects your medication: don't stop taking it on your own. Call your prescriber or pharmacist before doing anything. Stopping a prescribed drug abruptly can be more dangerous than the issue prompting the recall. Most drug-recall remedies route through the dispensing pharmacy, who'll either swap your supply for an unaffected lot or coordinate a refund with the manufacturer.
Pending LLM rewrite. Source: FDA_DRUG D-0210-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0204-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0215-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0197-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0205-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0202-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0208-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0206-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0209-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0213-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0199-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0203-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0200-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0214-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0207-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0211-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0212-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0201-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0198-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0216-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0179-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0196-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0191-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0188-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0194-2026.
Looking for a different category? Browse all recalls.